Outset Medical Reports Improved Q4 & FY25 Financials, Reduced Cash Burn, and Modest 2026 Revenue Guidance

summarizeSummary

Outset Medical reported improved Q4 and full-year 2025 financial results, showcasing expanded gross margins and a significant reduction in cash burn, alongside modest revenue growth and 2026 guidance.

check_boxKey Events

• Q4 & FY2025 Revenue Performance

  Full year 2025 revenue increased 5% to $119.5 million, while fourth quarter revenue slightly decreased by 2% to $28.9 million compared to the prior year.

• Significant Gross Margin Expansion

  GAAP gross margin significantly expanded to 42.4% in Q4 2025 (from 36.5% in Q4 2024) and to 39.1% for the full year 2025 (from 33.9% in 2024).

• Reduced Operating Expenses & Improved Net Loss

  Operating expenses declined 8% in Q4 and substantially for the full year 2025, contributing to an improved net loss of $19.5 million in Q4 and $81.7 million for FY2025.

• Strong Cash Position & Reduced Cash Burn

  The company ended 2025 with $173 million in cash and investments, having significantly reduced net cash used in operations to $46 million in 2025 from $116 million in 2024.

auto_awesomeAnalysis

Outset Medical's latest earnings report highlights significant operational improvements, including substantial gross margin expansion and a notable reduction in cash used in operations for 2025. While revenue growth remains modest, the company's strengthened cash position and disciplined expense management are critical for its long-term viability and path to profitability. Investors should monitor continued margin expansion and revenue acceleration in 2026.